Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exc ...

MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funded warrants in-lieu the ...

Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditionsMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech Ltd., an Is ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Murano Global Investments Plc (MRNO) is up 146% at $3.35 [3] - Kustom Entertainment, Inc. (KUST) is up 34% at $2.84 [3] - Ainos, Inc. (AIMD) is up 34% at $2.32 [3] - Stride, Inc. (LRN) is up 29% at $94.10 [3] - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is up 18% at $2.40 [3] - Battalion Oil Corporation (BATL) is up 16% at $3.83 [3] - C3.ai, Inc. (AI) is up 15% at $14.58 [3] - Lantronix, Inc. (LTRX) is up 14% at $7.87 [3] - Nextpower Inc. (NXT) is up 13% at $120.00 [3] - High Roller Technologies, Inc. (ROLR) is up 7% at $7.56 [3] Premarket Losers - Flora Growth Corp. (FLGC) is down 34% at $7.20 [4] - TEN Holdings, Inc. (XHLD) is down 29% at $2.47 [4] - Global Interactive Technologies, Inc. (GITS) is down 22% at $3.25 [4] - 5E Advanced Materials, Inc. (FEAM) is down 15% at $2.70 [4] - Vyome Holdings, Inc. (HIND) is down 14% at $2.79 [4] - Altimmune, Inc. (ALT) is down 11% at $5.48 [4] - BiomX Inc. (PHGE) is down 10% at $6.22 [4] - Qorvo, Inc. (QRVO) is down 9% at $74.94 [4] - Nuwellis, Inc. (NUWE) is down 9% at $3.45 [4] - Brenmiller Energy Ltd (BNRG) is down 9% at $2.90 [4]

Nuwellis Inc (NASDAQ:NUWE) stock is on fire. Shares of the tiny medical device maker surged more than 100% in pre-market trading Tuesday and were still up around 85% by 10 AM ET in early trading, as investors piled into a rare microcap healthcare narrative: patents, a boardroom reset, and a niche Big Pharma largely ignored.For a company with a market value near $2 million, that's a powerful cocktail.A Boardroom Reset Fuels SpeculationLate last week, Nuwellis disclosed a sweeping board shakeup, with three lo ...

MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer sh ...

Core Insights - Nuwellis, Inc. has received a new U.S. patent for advanced safety mechanisms in blood return line clamps used in extracorporeal blood filtration systems, enhancing its pediatric intellectual property portfolio [1][3][4] Group 1: Patent Issuance - The newly issued patent focuses on safety innovations aimed at improving blood flow control reliability in extracorporeal circuits, particularly for pediatric applications where precision and safety are crucial [2][3] - This patent follows a Notice of Allowance and supports the development of the Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System [3][4] Group 2: Company Commitment and Strategy - The CEO of Nuwellis emphasized that each issued patent signifies progress in building a strong foundation of protected innovation, reinforcing the company's commitment to engineering precision and safety for vulnerable patient populations [4] - The patent contributes to Nuwellis' expanding intellectual property portfolio, supporting its pediatric development roadmap and broader cardio-renal strategy [4][6] Group 3: Product Overview - The Vivian system is designed specifically for neonates and children, featuring integrated sensors for real-time monitoring and offering multiple therapies on a single platform [9] - The system targets an extracorporeal blood volume of 29–67 mL and is developed with input from pediatric ICU and nephrology teams to prioritize safety and simplicity [9]

Core Insights - Nuwellis, Inc. has reinforced its leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload through new real-world data presented at the 2025 ASN Kidney Week [1][2] Group 1: Study Findings - A retrospective analysis reviewed 69 cases treated with Aquadex from 2018 to 2024, demonstrating effective fluid removal in patients with various underlying conditions [2] - The analysis revealed an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among patients on vasopressor support [3] - The study emphasizes that Aquadex can be safely applied across a wide range of complex patients, aiding clinicians in achieving euvolemia when other measures are insufficient [4] Group 2: Clinical Relevance - The findings support precision ultrafiltration as a complement to traditional kidney replacement therapy, with moderate and individualized ultrafiltration rates linked to improved outcomes in critically ill patients [5] - Aquapheresis is increasingly relevant in nephrology and critical care, where controlled fluid removal can stabilize hemodynamics and support renal recovery [6] - The study reflects a shift in fluid management practices, highlighting its importance as a vital sign of patient stability [7] Group 3: Company Overview - Nuwellis, Inc. is dedicated to advancing cardio-renal care by enabling earlier, safer, and more controlled fluid management for patients [8] - The Aquadex SmartFlow system is designed for ultrafiltration therapy, indicated for patients with fluid overload unresponsive to medical management [9]

Core Insights - Nuwellis, Inc. has announced the initiation of an Aquadex Ultrafiltration Program at a leading children's hospital in the Northeastern U.S., indicating a growing adoption of the therapy in pediatric nephrology and cardiology [1][2] - The Aquadex system is being integrated into care pathways for complex cardiac and critical care cases, highlighting its clinical value and strategic importance in Nuwellis' long-term growth plan [2][3] - The company's growth in the pediatric market is driven by clinicians seeking reliable solutions for fluid management, with Aquadex becoming a trusted option in pediatric care [3][4] Company Overview - Nuwellis, Inc. is focused on transforming the lives of patients suffering from fluid overload through innovative medical technology, specifically the Aquadex SmartFlow® system for ultrafiltration therapy [6][7] - The Aquadex SmartFlow system is indicated for use in both adult and pediatric patients weighing 20 kg or more, providing a method for removing excess fluid in cases unresponsive to traditional medical management [7] Market Dynamics - The adoption of Aquadex is accelerating in high-acuity pediatric settings across the nation, with children's hospitals recognizing its value in managing fluid-sensitive patients [2][3] - The integration of Aquadex into pediatric care reflects a broader trend of hospitals seeking controlled and predictable approaches to fluid management, which is essential for fragile pediatric patients [4]